Saltar al contenido
Merck

Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies.

Movement disorders : official journal of the Movement Disorder Society (2018-03-24)
Daniel Erskine, Jinhui Ding, Alan J Thomas, Alice Kaganovich, Ahmad A Khundakar, Peter S Hanson, John-Paul Taylor, Ian G McKeith, Johannes Attems, Mark R Cookson, Christopher M Morris
RESUMEN

Dementia with Lewy bodies is characterized by transient clinical features, including fluctuating cognition and visual hallucinations, implicating dysfunction of cerebral hub regions, such as the pulvinar nuclei of the thalamus. However, the pulvinar is typically only mildly affected by Lewy body pathology in dementia with Lewy bodies, suggesting additional factors may account for its proposed dysfunction. We conducted a comprehensive analysis of postmortem pulvinar tissue using whole-transcriptome RNA sequencing, protein expression analysis, and histological evaluation. We identified 321 transcripts as significantly different between dementia with Lewy bodies cases and neurologically normal controls, with gene ontology pathway analysis suggesting the enrichment of transcripts related to synapses and positive regulation of immune functioning. At the protein level, proteins related to synaptic efficiency were decreased, and general synaptic markers remained intact. Analysis of glial subpopulations revealed astrogliosis without activated microglia, which was associated with synaptic changes but not neurodegenerative pathology. These results indicate that the pulvinar, a region with relatively low Lewy body pathological burden, manifests changes at the molecular level that differ from previous reports in a more severely affected region. We speculate that these alterations result from neurodegenerative changes in regions connected to the pulvinar and likely contribute to a variety of cognitive changes resulting from decreased cortical synchrony in dementia with Lewy bodies. © 2018 International Parkinson and Movement Disorder Society.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
6α-Naloxol solution, 1.0 mg/mL in methanol, certified reference material, Cerilliant®